• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊马替尼耐药慢性髓性白血病中miR-181c的下调

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.

作者信息

Mosakhani Neda, Mustjoki Satu, Knuutila Sakari

机构信息

Department of Pathology, Haartman Institute, and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

出版信息

Mol Cytogenet. 2013 Jul 16;6(1):27. doi: 10.1186/1755-8166-6-27.

DOI:10.1186/1755-8166-6-27
PMID:23866735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3751646/
Abstract

The association of microRNA alterations with progression and treatment outcome has been revealed in different types of cancers. To find miRNAs involved in imatinib response we performed miRNA microarray followed by RT-qPCR verification of 9 available diagnostic bone marrow core biopsies from 9 CML patients including 4 imatinib-resistant and 5 imatinib-responder patients. Only one differentially expressed miRNA, miR-181c, was found when the imatinib-resistant group was compared with imatinib-responders. Significant down-regulation of miR-181c in imatinib-resistant versus imatinib-responders was confirmed by qRT-PCR. Some miR-181c target genes such as PBX3, HSP90B1, NMT2 and RAD21 have been associated with drug response.

摘要

微小RNA改变与癌症进展及治疗结果之间的关联已在不同类型的癌症中得到揭示。为了找到参与伊马替尼反应的微小RNA，我们进行了微小RNA微阵列分析，随后对9例慢性粒细胞白血病患者的9份可用诊断性骨髓核心活检样本进行了逆转录定量聚合酶链反应验证，其中包括4例伊马替尼耐药患者和5例伊马替尼敏感患者。当将伊马替尼耐药组与伊马替尼敏感组进行比较时，仅发现一种差异表达的微小RNA，即miR-181c。通过定量逆转录聚合酶链反应证实，与伊马替尼敏感患者相比，伊马替尼耐药患者中miR-181c显著下调。一些miR-181c靶基因，如PBX3、HSP90B1、NMT2和RAD21，已被证明与药物反应有关。

相似文献

1
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia.伊马替尼耐药慢性髓性白血病中miR-181c的下调
Mol Cytogenet. 2013 Jul 16;6(1):27. doi: 10.1186/1755-8166-6-27.
2
Overexpression of resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2.过表达 通过靶向己糖激酶 2 使伊马替尼耐药的慢性髓系白血病细胞重新敏感化。
Biosci Rep. 2018 May 8;38(3). doi: 10.1042/BSR20171383. Print 2018 Jun 29.
3
Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.在慢性粒细胞白血病中，miR-181c的上调通过靶向ST8SIA4抑制化疗耐药性。
Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054.
4
Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.突尼斯慢性髓性白血病患者中miR-451的下调：对伊马替尼耐药的潜在影响
Hematology. 2017 May;22(4):201-207. doi: 10.1080/10245332.2016.1252020. Epub 2016 Nov 9.
5
Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.在慢性粒细胞白血病细胞系中鉴定并验证对伊马替尼治疗有反应的mRNA和微小RNA联合特征。
PLoS One. 2014 Dec 15;9(12):e115003. doi: 10.1371/journal.pone.0115003. eCollection 2014.
6
microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia.微小RNA表达谱分析作为慢性髓性白血病的辅助诊断和治疗预测工具
Neoplasma. 2015;62(6):949-58. doi: 10.4149/neo_2015_115.
7
Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients.miR-126 和 miR-122 表达的调控及伊马替尼治疗对其在慢性髓性白血病患者中表达的影响。
Oncol Res Treat. 2021;44(10):530-537. doi: 10.1159/000518722. Epub 2021 Aug 16.
8
MicroRNA 30a Mediated Autophagy and Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients.微小RNA 30a介导埃及慢性髓性白血病患者的自噬及伊马替尼反应
Indian J Hematol Blood Transfus. 2020 Jul;36(3):491-497. doi: 10.1007/s12288-019-01241-3. Epub 2019 Dec 12.
9
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.伊马替尼和波纳替尼对慢性髓性白血病自噬和微小RNA组的比较作用
Gene. 2017 Dec 30;637:173-180. doi: 10.1016/j.gene.2017.09.036. Epub 2017 Sep 20.
10
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.伊马替尼治疗下 K-562 细胞的 microRNA 谱分析：miR-212 和 miR-328 对 ABCG2 表达的影响。
Pharmacogenet Genomics. 2012 Mar;22(3):198-205. doi: 10.1097/FPC.0b013e328350012b.

引用本文的文献

1
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia.非编码RNA对慢性粒细胞白血病伊马替尼耐药性的影响。
Leuk Res Rep. 2025 Jul 10;24:100529. doi: 10.1016/j.lrr.2025.100529. eCollection 2025.
2
Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells.miR-142a的下调有助于增强小鼠慢性粒细胞白血病细胞的抗凋亡能力。
Front Oncol. 2021 Jul 27;11:718731. doi: 10.3389/fonc.2021.718731. eCollection 2021.
3
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.

本文引用的文献

1
Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.蛋白质组学分析表明，核心蛋白聚糖和内质网分子伴侣（HSP90B1）的高表达与乳腺癌转移和降低生存率相关。
PLoS One. 2012;7(2):e30992. doi: 10.1371/journal.pone.0030992. Epub 2012 Feb 20.
2
Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFα regulation and proliferation of hematopoietic progenitor cells.下调的 hsa-miR-181c 在范可尼贫血患者中的表达：对 TNFα 调节和造血祖细胞增殖的影响。
Blood. 2012 Mar 29;119(13):3042-9. doi: 10.1182/blood-2011-01-331017. Epub 2012 Feb 6.
3
miR-181c 通过靶向 GRP78 抑制 PI3K/Akt 通路增强卵巢癌细胞对紫杉醇的敏感性
Cancer Gene Ther. 2022 Jun;29(6):770-783. doi: 10.1038/s41417-021-00356-y. Epub 2021 Jun 18.
4
MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling.miR-320b/RAD21 轴通过 DNA 损伤修复信号影响肝癌对电离辐射治疗的放射敏感性。
Cancer Sci. 2021 Feb;112(2):575-588. doi: 10.1111/cas.14751. Epub 2020 Dec 31.
5
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.初治慢性髓性白血病患者中，对伊马替尼治疗有反应者与无反应者之间miR-142-5p的表达差异表明，其与致癌性ABL2、SRI、cKIT和MCL1信号通路存在关联，而这些信号通路对于治疗耐药性的产生至关重要。
Exp Hematol Oncol. 2020 Sep 26;9:26. doi: 10.1186/s40164-020-00183-1. eCollection 2020.
6
N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections.N-豆蔻酰转移酶作为癌症、免疫和感染中的甘氨酸和赖氨酸豆蔻酰转移酶。
ACS Chem Biol. 2020 Jul 17;15(7):1747-1758. doi: 10.1021/acschembio.0c00314. Epub 2020 Jun 10.
7
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.浅析 ABCB1/P-糖蛋白在慢性髓性白血病中的作用
Molecules. 2018 Jan 7;23(1):119. doi: 10.3390/molecules23010119.
8
MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.在慢性髓性白血病中，微小RNA-15a-5p通过靶向趋化因子配体10负向调节细胞存活和转移。
Am J Transl Res. 2017 Sep 15;9(9):4308-4316. eCollection 2017.
9
miR-150 Suppresses the Proliferation and Tumorigenicity of Leukemia Stem Cells by Targeting the Nanog Signaling Pathway.微小RNA-150通过靶向Nanog信号通路抑制白血病干细胞的增殖和致瘤性。
Front Pharmacol. 2016 Nov 18;7:439. doi: 10.3389/fphar.2016.00439. eCollection 2016.
10
Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.伊马替尼耐药慢性髓性白血病中微小RNA与基因的调控网络分析
Funct Integr Genomics. 2017 May;17(2-3):263-277. doi: 10.1007/s10142-016-0520-1. Epub 2016 Sep 16.
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
HOXA-PBX3 同源盒基因表达谱的上调与 miR-181 的下调相关，与细胞遗传学异常 AML 患者的不良预后相关。
Blood. 2012 Mar 8;119(10):2314-24. doi: 10.1182/blood-2011-10-386235. Epub 2012 Jan 17.
4
Non-coding RNAs for medical practice in oncology.用于肿瘤学医学实践的非编码RNA
Keio J Med. 2011;60(4):106-13. doi: 10.2302/kjm.60.106.
5
MicroRNA pharmacogenomics: post-transcriptional regulation of drug response.miRNA 药物基因组学：药物反应的转录后调控。
Trends Mol Med. 2011 Aug;17(8):412-23. doi: 10.1016/j.molmed.2011.04.003. Epub 2011 Jun 7.
6
Expression patterns of microRNAs associated with CML phases and their disease related targets.与 CML 各阶段相关的 microRNAs 的表达模式及其与疾病相关的靶标。
Mol Cancer. 2011 Apr 18;10:41. doi: 10.1186/1476-4598-10-41.
7
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.增强的 RAD21 黏合蛋白表达与高级别 luminal、基底和 HER2 乳腺癌的不良预后和化疗耐药相关。
Breast Cancer Res. 2011 Jan 21;13(1):R9. doi: 10.1186/bcr2814.
8
Human activated CD4(+) T lymphocytes increase IL-2 expression by downregulating microRNA-181c.人源激活的 CD4(+) T 淋巴细胞通过下调 microRNA-181c 增加 IL-2 的表达。
Mol Immunol. 2011 Jan;48(4):592-9. doi: 10.1016/j.molimm.2010.10.021. Epub 2010 Nov 26.
9
MicroRNA microarrays on archive bone marrow core biopsies of leukemias--method validation.白血病存档骨髓芯活检的 microRNA 微阵列 - 方法验证。
Leuk Res. 2011 Feb;35(2):188-95. doi: 10.1016/j.leukres.2010.08.005. Epub 2010 Sep 9.
10
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.Lyn 激酶依赖性调节 miR181 和髓样细胞白血病-1 表达：对髓系白血病耐药性的影响。
Mol Pharmacol. 2010 Nov;78(5):811-7. doi: 10.1124/mol.110.066258. Epub 2010 Aug 6.